Abstract 1499
Background
Tumor growth depends on pro-angiogenic vascular endothelial growth factors (VEGF-A/-B) via binding to VEGF receptors (VEGFR1 and VEGFR2) that are biomarkers of tumor angiogenesis. Importantly, interfering with this interaction by small molecules impairs tumor growth and angiogenesis.
Methods
A novel peptide (known as VGB3) was synthesized using a solid-phase peptide synthesis (SPPS) procedure on 2-chlorotrityl chloride (2-CTC) resin. A disulfide bridge was formed in the peptide and it was purified using RP-HPLC. Recombinant His-tagged VEGFR1D2 obtained from inclusion bodies and purified on a Ni2+-NTA agarose resin. The equilibrium constant for the binding of VGB3 to VEGFR1-D2 molecule was determined by microscale thermophoresis (MST). The accumulation of the peptide in 4T1 mammary carcinoma tumors (MCTs) was assessed using 2D optical imaging. Anti-angiogenic activity of VGB3 were investigated using MTT, scratch assay, and two- as well as three-dimensional angiogenesis assays. Downstream signaling pathways were assessed by quantitative estimation of protein expression using western blotting and immunohistochemistry. (IHC).
Results
We have indicated that VGB3 is able to block VEGFR1-D2 in human umbilical vein endothelial cells (HUVECs) and 4T1 mammary carcinoma tumor (MCT) cells. This resulted in inhibition in proliferation of HUVEC, 4T1 MCT, and U87 glioblastoma cells and MST results reveals that VGB3 is a high-affinity (Kd=1.96± 0.69 µM, n = 3, P < 0.0001) binder to VEGFR1-D2. Moreover, fluorescence imaging in Balb/c mice demonstrated that fluorescein isothiocyanate (FITC)-VGB3 accumulated in tumors. VEGFA-stimulated proliferation, migration, and 2 and 3D tube formation in HUVECs were strongly inhibited by VGB3 (n = 3, P < 0.0001). In a murine 4T1 MCT model, VGB3 strongly inhibited AKT and ERK1/2 phosphorylation and tumor cell downstream signaling pathways associated with proliferation, migration, and angiogenesis, and led to the increased apoptosis index and suppression of systematic spreading of the tumor compared to PBS-treated controls.
Conclusions
These results indicate that VGB3 may be applicable for antiangiogenic and antitumor therapy.
Clinical trial identification
Editorial acknowledgement
S. Mohsen Asghari and Prof. Matthew Groves
Legal entity responsible for the study
S. Mohsen Asghari and Matthew Groves.
Funding
University of Guilan.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4526 - Long-term outcome of neoadjuvant tyrosine kinase inhibitors (TKI) in locally advanced dermatofibrosarcoma protuberans (DFSP)
Presenter: Jessica Beaziz
Session: Poster Display session 1
Resources:
Abstract
1214 - Neo-adjuvant (NA) Imatinib for gastrointestinal stromal tumours (GISTs): What is the optimal length of treatment?
Presenter: Tom Wilson
Session: Poster Display session 1
Resources:
Abstract
2690 - Gastrointestinal Stromal Tumours (GIST) in adolescents and young adults (AYA)
Presenter: Nikki Ijzerman
Session: Poster Display session 1
Resources:
Abstract
4558 - Radiomics improves response evaluation for desmoid tumors treated with chemotherapy
Presenter: Amandine Crombe
Session: Poster Display session 1
Resources:
Abstract
2751 - Radiomics of gastrointestinal stromal tumors; risk classification based on computed tomography images – a pilot study
Presenter: Milea Timbergen
Session: Poster Display session 1
Resources:
Abstract
2737 - Differentiating well-differentiated liposarcomas from lipomas using a radiomics approach
Presenter: Melissa Vos
Session: Poster Display session 1
Resources:
Abstract
1282 - The immune landscape of chondrosarcoma reveals an anti inflammatory environment
Presenter: Iseulys Richert
Session: Poster Display session 1
Resources:
Abstract
1572 - Impact of Immunotherapy and Targeted Therapy on Tumor Growth Rate in Sarcoma
Presenter: Esmail Al-ezzi
Session: Poster Display session 1
Resources:
Abstract
3414 - DNA methylation profiles of angiosarcoma subtypes.
Presenter: Marije Weidema
Session: Poster Display session 1
Resources:
Abstract
3411 - Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As and BTN3A1 in patients with metastatic gastrointestinal stromal tumors (mGISTs)
Presenter: Daniele Fanale
Session: Poster Display session 1
Resources:
Abstract